ZYNE — Zynerba Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
Brief: Zynerba Pharmaceuticals Q3 Loss Per Share $0.26
Brief: Zynerba Pharmaceuticals Initiates Pivotal Trial Of Zygel In Fragile X Syndrome
Brief: Zynerba Pharmaceuticals Presents Longer Term Tolerability And Efficacy Data Of Zygel In Children And Adolescents With Autism Spectrum Disorder At Society For Study Of Behavioural Phenotypes Conference 2021
Brief: Zynerba Pharmaceuticals Announces Publication Of Results Of Phase 2 Study Of Zygel In Children And Adolescents With Developmental And Epileptic Encephalopathies
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Zynerba Pharmaceuticals Reports Q2 Loss Per Share Of $0.25
Zynerba Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Zynerba Pharmaceuticals Announces Adjournment Of Annual Meeting
Brief: Zynerba Pharmaceuticals Announces Adjournment Of Annual Meeting
Brief: Zynerba Pharmaceuticals - On May 12, Court Issued Order Providing For Preliminary Approval Of Proposed Settlement Of Claims Asserted On Behalf Of Co
Zynerba Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Zynerba Pharmaceuticals Reports Q1 Loss Per Share Of $0.20
Brief: Zynerba Pharma Reports Q4 Loss Per Share Of $0.33
Can't stop, won't stop: Pot stocks rally re-fueled by GW Pharma merger
Can't stop, won't stop: Pot stocks rally re-fueled by GW Pharma merger
U.S. STOCKS ON THE MOVE-Jabil, Zynerba, Fisker
Zynerba: Down after FDA recommends additional trial of neurological disorder drug
Brief: Zynerba Pharmaceuticals Provides Regulatory Update On Zygel In Fragile X Syndrome
Brief: Zynerba Pharmaceuticals Presents New Data In Two Posters At 2020 Annual Meeting Of The American Epilepsy Society